Lund, Sweden

Eugen Jan Karol Axcrona

This inventor holds 1 USPTO granted patent. Top assignee: Hansa Medical Ab. Active years: 2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eugen Jan Karol Axcrona. Retrieved from https://idiyas.com/inventor/eugen-jan-karol-axcrona

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Eugen Jan Karol Axcrona

Introduction

Eugen Jan Karol Axcrona is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of medical science, particularly in the development of cytostatic agents. His work focuses on addressing diseases that involve undesired cell proliferation.

Latest Patents

Eugen Axcrona holds a patent for the "Use of protein H as cytostatic agent." This patent details the application of protein H, along with its fragments or derivatives, as cytostatic agents, especially in the treatment of diseases characterized by unwanted cell growth. This innovation has the potential to impact cancer treatment and other related medical fields.

Career Highlights

Axcrona is associated with Hansa Medical AB, a company that specializes in developing innovative therapies for severe diseases. His work at Hansa Medical has allowed him to contribute to advancements in medical treatments and research.

Collaborations

Eugen has collaborated with notable colleagues, including Lars H Björck and Inga-Maria Frick. These partnerships have fostered a collaborative environment that enhances research and development efforts in their field.

Conclusion

Eugen Jan Karol Axcrona's contributions to the field of cytostatic agents exemplify the importance of innovation in medical science. His work continues to pave the way for advancements in treatment options for diseases involving undesired cell proliferation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…